LLY

780.76

+0.43%↑

JNJ

155.91

+0.24%↑

UNH

308.74

-1.39%↓

ABBV

188.97

-1.11%↓

ABT

134.34

-0.08%↓

LLY

780.76

+0.43%↑

JNJ

155.91

+0.24%↑

UNH

308.74

-1.39%↓

ABBV

188.97

-1.11%↓

ABT

134.34

-0.08%↓

LLY

780.76

+0.43%↑

JNJ

155.91

+0.24%↑

UNH

308.74

-1.39%↓

ABBV

188.97

-1.11%↓

ABT

134.34

-0.08%↓

LLY

780.76

+0.43%↑

JNJ

155.91

+0.24%↑

UNH

308.74

-1.39%↓

ABBV

188.97

-1.11%↓

ABT

134.34

-0.08%↓

LLY

780.76

+0.43%↑

JNJ

155.91

+0.24%↑

UNH

308.74

-1.39%↓

ABBV

188.97

-1.11%↓

ABT

134.34

-0.08%↓

Search

Palatin Technologies Inc

Uždarymo kaina

0.09

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.09

Max

0.09

Palatin Technologies Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Akcijų palyginimas

Kainos pokytis

Palatin Technologies Inc Prognozė

Apie bendrovę Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.